• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Improving clinical outcomes for naltrexone as a management of problem alcohol use.改善纳曲酮作为问题性酒精使用管理手段的临床疗效。
Br J Clin Pharmacol. 2013 Nov;76(5):632-41. doi: 10.1111/j.1365-2125.2012.04452.x.
2
Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.纳曲酮长效制剂治疗阿片类物质和酒精依赖:系统评价。
CNS Neurosci Ther. 2011 Dec;17(6):629-36. doi: 10.1111/j.1755-5949.2010.00194.x.
3
Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems.纳曲酮:现有缓释药物传递系统和新兴纳米基系统的综述。
J Control Release. 2014 Jun 10;183:154-66. doi: 10.1016/j.jconrel.2014.03.046. Epub 2014 Apr 2.
4
A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence.
Expert Opin Pharmacother. 2006 Jun;7(8):1065-73. doi: 10.1517/14656566.7.8.1065.
5
Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON).在初级保健中,用于治疗酒精依赖的延长释放与口服纳曲酮(XON)。
Contemp Clin Trials. 2019 Jun;81:102-109. doi: 10.1016/j.cct.2019.04.006. Epub 2019 Apr 12.
6
Vivitrex (Alkermes/Cephalon).维维曲(阿尔克姆斯/ Cephalon公司)。
Curr Opin Investig Drugs. 2006 Jan;7(1):81-8.
7
Efficacy and tolerability of naltrexone in the management of alcohol dependence.纳曲酮治疗酒精依赖的疗效和耐受性。
Curr Pharm Des. 2010;16(19):2091-7. doi: 10.2174/138161210791516459.
8
Naltrexone: Not Just for Opioids Anymore.纳曲酮:不再仅仅用于阿片类药物。
J Med Toxicol. 2016 Mar;12(1):71-5. doi: 10.1007/s13181-015-0512-x.
9
Long-acting depot formulations of naltrexone for heroin dependence: a review.长效纳曲酮混悬液用于海洛因依赖:综述。
Curr Opin Psychiatry. 2010 May;23(3):210-4. doi: 10.1097/YCO.0b013e3283386578.
10
What place does naltrexone have in the treatment of alcoholism?纳曲酮在酒精中毒治疗中处于什么地位?
CNS Drugs. 2004;18(9):547-60. doi: 10.2165/00023210-200418090-00001.

引用本文的文献

1
The Safety of Alcohol Pharmacotherapies in Pregnancy: A Scoping Review of Human and Animal Research.孕期酒精药物治疗的安全性:一项关于人类和动物研究的范围综述
CNS Drugs. 2025 Jan;39(1):23-37. doi: 10.1007/s40263-024-01126-8. Epub 2024 Oct 10.
2
Effects of Naltrexone on Expression of Lipid Metabolism-Related Proteins in Liver Steatosis Induced by Endoplasmic Reticulum Stress in Mice.内质网应激诱导的小鼠肝脂肪变性中纳曲酮对脂代谢相关蛋白表达的影响。
Contrast Media Mol Imaging. 2022 May 29;2022:6572499. doi: 10.1155/2022/6572499. eCollection 2022.
3
New Biodegradable Poly(l-lactide)-Block-Poly(propylene adipate) Copolymer Microparticles for Long-Acting Injectables of Naltrexone Drug.用于纳曲酮药物长效注射剂的新型可生物降解聚(L-丙交酯)-嵌段-聚(己二酸丙酯)共聚物微粒
Polymers (Basel). 2020 Apr 7;12(4):852. doi: 10.3390/polym12040852.
4
Amphiphilic Block Copolymer Microspheres Derived from Castor Oil, Poly(ε-carpolactone), and Poly(ethylene glycol): Preparation, Characterization and Application in Naltrexone Drug Delivery.源自蓖麻油、聚(ε-己内酯)和聚乙二醇的两亲性嵌段共聚物微球:制备、表征及其在纳曲酮药物递送中的应用
Materials (Basel). 2018 Oct 16;11(10):1996. doi: 10.3390/ma11101996.
5
A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction.一种用于筛选治疗成瘾药物的酒精中毒基因动物模型。
Int Rev Neurobiol. 2016;126:179-261. doi: 10.1016/bs.irn.2016.02.017. Epub 2016 Mar 21.
6
Drugs for addiction: a therapeutic area in need of a 'shot in the arm'.用于成瘾治疗的药物:一个急需“强心针”的治疗领域。
Br J Clin Pharmacol. 2014 Feb;77(2):225-7. doi: 10.1111/bcp.12316.

本文引用的文献

1
Type I and Type II Alcoholism: An Update.I型和II型酒精中毒:最新进展。
Alcohol Health Res World. 1996;20(1):18-23.
2
Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.纳曲酮对亚急性治疗和酒吧实验室范式中饮酒影响的修饰:阿片受体 mu 型 1(OPRM1)和多巴胺转运体(SLC6A3)基因的影响。
Alcohol Clin Exp Res. 2012 Nov;36(11):2000-7. doi: 10.1111/j.1530-0277.2012.01807.x. Epub 2012 May 2.
3
Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study.通过行为经济学了解亚裔美国人中纳曲酮的作用机制和药物遗传学:一项初步研究。
Exp Clin Psychopharmacol. 2012 Jun;20(3):181-90. doi: 10.1037/a0027379. Epub 2012 Mar 19.
4
Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.亚洲裔美国人中美沙酮的药物遗传学:一项随机安慰剂对照实验室研究。
Neuropsychopharmacology. 2012 Jan;37(2):445-55. doi: 10.1038/npp.2011.192. Epub 2011 Sep 7.
5
Safety, tolerability, and feasibility of high-dose naltrexone in alcohol dependence: an open-label study.高剂量纳曲酮治疗酒精依赖的安全性、耐受性和可行性:一项开放标签研究。
Hum Psychopharmacol. 2011 Mar;26(2):125-32. doi: 10.1002/hup.1183. Epub 2011 Mar 16.
6
Intramuscular extended-release naltrexone: current evidence.肌肉内缓释纳曲酮:现有证据。
Ann N Y Acad Sci. 2011 Jan;1216:144-66. doi: 10.1111/j.1749-6632.2010.05900.x.
7
Retention in naltrexone implant treatment for opioid dependence.纳曲酮植入物治疗阿片类药物依赖的保持率。
Drug Alcohol Depend. 2010 Sep 1;111(1-2):166-9. doi: 10.1016/j.drugalcdep.2010.03.021. Epub 2010 May 31.
8
Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone.口服或植入用纳曲酮治疗的海洛因使用者出现觅药和复吸的风险因素。
Biol Psychiatry. 2010 Aug 1;68(3):296-302. doi: 10.1016/j.biopsych.2010.04.003. Epub 2010 May 26.
9
Efficacy and tolerability of naltrexone in the management of alcohol dependence.纳曲酮治疗酒精依赖的疗效和耐受性。
Curr Pharm Des. 2010;16(19):2091-7. doi: 10.2174/138161210791516459.
10
Naltrexone implants compared to methadone: outcomes six months after prison release.纳曲酮植入物与美沙酮比较:出狱后六个月的结果。
Eur Addict Res. 2010;16(3):139-45. doi: 10.1159/000313336. Epub 2010 Apr 26.

改善纳曲酮作为问题性酒精使用管理手段的临床疗效。

Improving clinical outcomes for naltrexone as a management of problem alcohol use.

作者信息

Hulse Gary K

机构信息

Addiction Medicine, School of Psychiatry & Clinical Neurosciences (M521), The University of Western Australia, Crawley, WA, Australia.

出版信息

Br J Clin Pharmacol. 2013 Nov;76(5):632-41. doi: 10.1111/j.1365-2125.2012.04452.x.

DOI:10.1111/j.1365-2125.2012.04452.x
PMID:22946873
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3853523/
Abstract

Despite being a relatively effective and safe treatment, the clinical management of alcohol abuse/dependence by oral naltrexone can be compromised due to the patient's non-compliance with daily use of this medication. Over the past decade an increasing body of research has suggested that the use of sustained release depot naltrexone preparations can overcome this issue and deliver improved clinical outcomes. However, at the same time, research findings from diverse areas of pharmacogenetics, neurobiology and behavioural psychology have also been converging to identify variables including genetic markers, patient psychosocial characteristics and drug use history differences, or clusters of these variables that play a major role in mediating the response of alcohol abuse/dependent persons to treatment by naltrexone. While this article does not attempt to review all available data pertaining to an individual alcohol dependent patient's response to treatment by naltrexone, it does identify relevant research areas and highlights the importance of data arising from them. The characterization of clinical markers, to identify those patients who are most likely to benefit from naltrexone and to tailor a more individual naltrexone treatment, will ultimately provide significant benefit to both patients and clinicians by optimizing treatment outcome.

摘要

尽管口服纳曲酮是一种相对有效且安全的治疗方法,但由于患者不遵守每日用药规定,酒精滥用/依赖的临床管理可能会受到影响。在过去十年中,越来越多的研究表明,使用缓释长效纳曲酮制剂可以克服这个问题,并带来更好的临床效果。然而,与此同时,来自药物遗传学、神经生物学和行为心理学等不同领域的研究结果也趋于一致,以确定包括基因标记、患者心理社会特征和药物使用史差异等变量,或这些变量的组合,它们在介导酒精滥用/依赖者对纳曲酮治疗的反应中起主要作用。虽然本文不试图回顾与个体酒精依赖患者对纳曲酮治疗反应相关的所有现有数据,但它确实确定了相关研究领域,并强调了这些领域产生的数据的重要性。临床标志物的特征化,以识别那些最有可能从纳曲酮中获益的患者,并定制更个性化的纳曲酮治疗,最终将通过优化治疗结果为患者和临床医生带来显著益处。